Iruplinalkib

DRUG2 trials

Sponsors

Jinming Yu, Shanghai Pulmonary Hospital, Shanghai, China

Conditions

Non-small Cell Lung Cancer (NSCLC)Potentially Resectable ALK Positive Non-Small Cell Lung Cancer

Phase 2

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Not yet recruitingNCT06282536

Shanghai Pulmonary Hospital, Shanghai, ChinaPotentially Resectable ALK Positive Non-Small Cell Lung Cancer

Start: 2024-03-31End: 2029-12-31Target: 20Updated: 2024-02-28

Unknown Phase

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

RecruitingNCT05991895

Jinming YuNon-small Cell Lung Cancer (NSCLC)

Start: 2023-07-24End: 2026-07-31Target: 5000Updated: 2023-08-15